Revision of USP Chapters <782> Vibrational Circular Dichroism Spectroscopy and <1782> Vibrational Circular Dichroism Spectroscopy - Theory and Practice

Recommendation
Monday, 29 September 2025 14.00 - 17.00 h
In the Pharmacopeial Forum, PF 49(3), proposals of revised USP General Chapters <782> Vibrational Circular Dichroism Spectroscopy and <1782> Vibrational Circular Dichroism Spectroscopy - Theory and Practice were published for comments.
In both cases, it is about to replace carbon tetrachloride (CCl4), a highly hazardous reagents, with deuterated chloroform (CDCl3), a less toxic solvent. The briefing notes state that "this revision is aligned with USP policy to contribute to global efforts to minimize negative environmental impact." In addition to that change, minor editorial changes to update the chapters to current USP style have been made.
Concerning Chapter <782> Vibrational Circular Dichroism Spectroscopy, the new proposal is based on the version of the chapter official as of 01 December 2016. The changes are limited to the replacement of carbon tetrachloride by deuterated chloroform in several places in the subchapters 2 and 3.
The draft of the new Chapter <1782> Vibrational Circular Dichroism Spectroscopy - Theory and Practice is based on the version of the chapter official as of 01 May 2020. In addition to the replacement of the solvent in the running text, it also provides new figures of spectra recorded from substances dissolved in deuterated chloroform.
Comments on both revised chapters can be submitted from now on until 31 July 2023.
The drafts are available after registration to the Pharmacopeial Forum.
Related GMP News
15.09.2025USP-NF Stimuli Article on Apex Vessels used in Dissolution Testing: Corrected Version Published
27.08.2025FDA Warning Letter: Missing Identity Tests, Unverified CoAs, and Inadequate DEG/EG Controls
20.08.2025USP Responds to Comments on Chapter <202> HPTLC Identification of Fixed Oils
13.08.2025USP publishes Comments rereived on Chapter <317>
13.08.2025FDA Issues Warning Letter to Contract Testing Laboratory for Inadequate OOS Investigations
06.08.2025EMA publishes Overview of Comments received on ICH M13B Guideline on Bioequivalence